First-line treatment of advanced ALK-positive non-small-cell lung cancer

References

• Cancer.gov [Homepage on the Internet]Atlanta, GAAmerican Cancer Society Available from: http://www.cancer.gov/Accessed April 1, 2015
   Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• ScagliottiGVDe MarinisFRinaldiMPhase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancerJ Clin Oncol200220214285429112409326
   PubMed Web of Science ®Google Scholar
• MetroGCrinòLNovel molecular trends in the management of advanced nonsmall-cell lung cancerExpert Rev Anticancer Ther201212672973222716489
   PubMedGoogle Scholar
• ReungwetwattanaTDyGKTargeted therapies in development for non-small cell lung cancerJ Carcinog2013122224574860
   PubMedGoogle Scholar
• ShawATSolomonBTargeting anaplastic lymphoma kinase in lung cancerClin Cancer Res20111782081208621288922
   PubMed Web of Science ®Google Scholar
• MartelliMPSozziGHernandezLEML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissuesAm J Pathol2009174266167019147828
   PubMed Web of Science ®Google Scholar
• LeeJABubendorfLStahelRPetersSTesting for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectivesExpert Rev Anticancer Ther201313562563623617353
   PubMed Web of Science ®Google Scholar
• YiESChungJHKuligKKerrKMDetection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature reviewMol Diagn Ther201216314315022506598
   PubMed Web of Science ®Google Scholar
• WeickhardtAJAisnerDLFranklinWAVarella-GarciaMDoebeleRCCamidgeDRDiagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancerCancer201311981467147723280244
   PubMed Web of Science ®Google Scholar
• SodaMIsobeKInoueAA prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancerClin Cancer Res201218205682568922908099
   PubMed Web of Science ®Google Scholar
• WuYCChangICWangCLComparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in TaiwanPLoS One201388e7083923951022
   PubMed Web of Science ®Google Scholar
• WallanderMLGeiersbachKBTrippSRLayfieldLJComparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testingArch Pathol Lab Med2012136779680322742552
   PubMed Web of Science ®Google Scholar
• TeixidoCKarachaliouNPegVGimenez-CapitanARosellRConcordance of IHC, FISH and RT-PCR for EML4-ALK rearrangementsTransl Lung Cancer Res201432707425806283
   PubMedGoogle Scholar
• Mino-KenudsonMChirieacLRLawKA novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistryClin Cancer Res20101651561157120179225
   PubMed Web of Science ®Google Scholar
• KelleherFCMcDermottRThe emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase geneEur J Cancer201046132357236820451371
   PubMed Web of Science ®Google Scholar
• PeledNPalmerGHirschFRNext-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancerJ Thorac Oncol201279e14e1622895149
   PubMed Web of Science ®Google Scholar
• AliSMOuS-HIHeJIdentifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinomaPoster presented at: Proceedings of the 50th Annual Meeting of American Society of Clinical OncologyMay 30–June 3, 2014Chicago, IL
   Google Scholar
• Catalogue of somatic mutations in cancerCambridge, UKWellcome Trust Sanger Institute Available from: http://cancer.sanger.ac.uk/cosmic/fusionAccessed May 4, 2015
   Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• CamidgeDRDoebeleRCTreating ALK-positive lung cancer-early successes and future challengesNat Rev Clin Oncol20129526827722473102
   PubMed Web of Science ®Google Scholar
• BlackhallFHPetersSBubendorfLPrevalence and clinical outcomes for patients with ALK-positive resected stage I–III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape ProjectJ Clin Oncol201432252780278725071109
   PubMed Web of Science ®Google Scholar
• http://www.wcrf.org/int/cancer-facts-figures/worldwide-data [Homepage on the Internet]Cancer Incidence and Mortality Worldwide: IARC CancerBase Number 11 [Internet]Lyon, FranceInternational Agency for Research on Cancer2014 Available from: http://globocan.iarc.fr/Accessed January 16, 2015
   Google Scholar
• TakahashiTSonobeMKobayashiMClinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion geneAnn Surg Oncol201017388989720183914
   PubMed Web of Science ®Google Scholar
• YamamotoSKornRLOkluRALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterizationRadiology2014272256857624885982
   PubMed Web of Science ®Google Scholar
• CamidgeDRKonoSALuXAnaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexedJ Thorac Oncol20116477478021336183
   PubMed Web of Science ®Google Scholar
• LeeJOKimTMLeeSHAnaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancerJ Thorac Oncol2011691474148021642865
   PubMed Web of Science ®Google Scholar
• ShawATVargheseAMSolomonBJPemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerAnn Oncol2013241596622887466
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchiKA mouse model for EML4-ALK-positive lung cancerProc Natl Acad Sci U S A200810550198931989719064915
   PubMed Web of Science ®Google Scholar
• CuiJKaniaRSEdwardsMPCrizotinibLackeyKRothBMedicinal Chemistry Approaches to Personalized Medicine59 Chapter 3, Section 3.3New York, NYWiley2014
   Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507
   PubMed Web of Science ®Google Scholar
• CrinòLKimDRielyGJInitial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005Poster presented at: Proceedings of the 47th Annual Meeting of American Society of Clinical OncologyJune 3–7, 2011Chicago, IL
   Google Scholar
• KimDAhnMShiYUpdated results of a global Phase II study with crizotinib in advanced ALK positive non-small cell lung cancer (NSCLC) [abstract]Ann Oncol201223Suppl 9402
   Google Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discov20144666267324675041
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteErlotinib hydrochloride or crizotinib and chemoradiation therapy in treating patients with stage iii non-small cell lung cancer (NSCLC) Available from: https://clinicaltrials.gov/ct2/show/results/NCT01822496. NLM Identifier: NCT01822496Accessed July 24, 2015
   Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWFirst-line crizotinib versus hemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• LovlyCMHeuckmannJMde StanchinaEInsights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitorsCancer Res201171144920493121613408
   PubMed Web of Science ®Google Scholar
• ShawATKimDWMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med2014370131189119724670165
   PubMed Web of Science ®Google Scholar
• KimDWMehraRTanSWCeritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trialPoster presented at: Proceedings of the 50th Annual Meeting of American Society of Clinical OncologyMay 30–June 3, 2014Chicago; IL
   Google Scholar
• GainorJFTanDSDe PaoTProgression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and certinibClin Cancer Res201521122745275225724526
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsLDK378 versus chemotherapy in previously untreated patients with ALK rearranged non-small cell lung cancer Available at: https://clinicaltrials.gov/ct2/results?term=NCT01828099&Search=Search. NLM Identifier: NCT01828099Accessed September 1, 2014
   Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell201119567969021575866
   PubMed Web of Science ®Google Scholar
• KodamaTTsukaguchiTYoshidaMKondohOSakamotoHSelective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistanceCancer Lett2014351221522124887559
   PubMed Web of Science ®Google Scholar
• SetoTKiuraKNishioMCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyLancet Oncol201314759059823639470
   PubMed Web of Science ®Google Scholar
• GadgeelSMGandhiLRielyGJSafety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyLancet Oncol201415101119112825153538
   PubMed Web of Science ®Google Scholar
• NakagawaKHidaTSetoTAntitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence studyPoster presented at: Proceedings of the 50th Annual Meeting of American Society of Clinical OncologyMay 30–June 3, 2014Chicago, IL
   Google Scholar
• DoebeleRCLuXSumeyCOncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancerCancer2012118184502451122282022
   PubMed Web of Science ®Google Scholar
• KangHJLimHJParkJSComparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinomaRespir Med2014108238839424361161
   PubMed Web of Science ®Google Scholar
• GoftonTEGraberJCarverAIdentifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysisJ Neurooncol2012108352753422467138
   PubMed Web of Science ®Google Scholar
• BaumlJMickRZhangYDeterminants of survival in advanced non-small-cell lung cancer in the era of targeted therapiesClin Lung Cancer201314558159123827517
   PubMed Web of Science ®Google Scholar
• BarlesiFGervaisRLenaHPemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)Ann Oncol201122112466247021321089
   PubMed Web of Science ®Google Scholar
• KumthekarPGrimmSAAvramAJPharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastasesJ Neurooncol2013112224725523354655
   PubMed Web of Science ®Google Scholar
• KanedaHOkamotoINakagawaKRapid response of brain metastasis to crizotinib in a patients with ALK rearrangement – positive non-small-cell lung cancerJ Thorac Oncol201384e32e3323486271
   PubMed Web of Science ®Google Scholar
• CostaDBKobayashiSPandyaSSCSF concentration of the anaplastic lymphoma kinase inhibitor crizotinibJ Clin Oncol20112915e443e44521422405
   PubMed Web of Science ®Google Scholar
• GainorJFOuSHLoganJBorgesLFShawATThe central nervous system as a sanctuary site in ALK-positive non-small cell lung cancerJ Thorac Oncol20138121570157324389440
   PubMed Web of Science ®Google Scholar
• WeickhardtAJScheierBBurkeJMLocal ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancerJ Thorac Oncol20127121807181423154552
   PubMed Web of Science ®Google Scholar
• SteuerCERamalingamSSALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsCancer2014120162392240224853389
   PubMed Web of Science ®Google Scholar
• GainorJFFribouletJKatayamaREvolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs)Poster presented at: Proceedings of the 50th Annual Meeting of American Society of Clinical OncologyMay 30–June 3, 2014Chicago, IL
   Google Scholar
• KatayamaRFribouletLKoikeSTwo novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibClin Cancer Res201420225686569625228534
   PubMed Web of Science ®Google Scholar
• OuSHGreeboweJKhanZUI 1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to certinibLung Cancer201588223123425736571
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci U S A2011108187535754021502504
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• SasakiTKoivunenJOginoAA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsCancer Res201171186051606021791641
   PubMed Web of Science ®Google Scholar
• KogitaATogashiYHayashiHActivated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancerInt J Oncol20154631025103025502629
   PubMed Web of Science ®Google Scholar
• GoujiTTakashiSMitsuhiroJYukitoICrizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?J Thorac Oncol201493e27e2824518097
   PubMed Web of Science ®Google Scholar
• CrystalASShawATSequistLVPatient-derived models of acquired resistance can identify effective drug combinations for cancerScience201434662161480148625394791
   PubMed Web of Science ®Google Scholar
• OtaKAzumaKKawaharaAInduction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancerClin Cancer Res Epub2015527
   Web of Science ®Google Scholar
• news.bms.com. [Homepage on the Internet]Bristol-Myers squibb announces collaboration to evaluate opdivo (nivolumab) in combination with targeted therapies from novartis to treat non-small cell lung cancer (NSCLC) Available from: http://news.bms.com/press-release/rd-news/bristol-myers-squibb-announces-collaboration-evaluate-opdivo-nivolumab-combinaAccessed July 24, 2015
   Google Scholar
• GainorJFSequistLVShawATClinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC)Poster presented at: Proceedings of the 51st Annual Meeting of American Society of Clinical OncologyMay 29–June 2, 2015Chicago, IL
   Google Scholar
• RiveraVMWangFAnjumRAP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLCCell20121100
   Google Scholar
• MologniLCecconMPirolaANPM/ALK mutants resistant to ASP 3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922Oncotarget2015685720573425749034
   PubMed Web of Science ®Google Scholar
• ArdiniEMenichincheriMDe PontiCCharacterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models [EORTC-NCIAACR abstract A243]Mol Cancer Ther2009812 SupplA244
   Web of Science ®Google Scholar
• ArdiniEMenichincheriMBanfiPIn vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori [EORTC-NCI-AACR abstract A232]Mol Cancer Ther20111011 SupplA232
   Google Scholar
• De BraudFGPillaLNigerMPhase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterationsPoster presented at: Proceedings of the 50th Annual Meeting of American Society of Clinical OncologyMay 30–June 3, 2014Chicago, IL
   Google Scholar
• HornLInfanteJRBlumenscheinGRA phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumorsPoster presented at: Proceedings of the 50th Annual Meeting of American Society of Clinical OncologyMay 30–June 3, 2014Chicago, IL
   Google Scholar
• NeckersLHsp90 inhibitors as novel cancer chemotherapeutic agentsTrends Mol Med20028S55S6111927289
   PubMed Web of Science ®Google Scholar
• ChenZSasakiTTanXInhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogeneCancer Res201070239827983620952506
   PubMed Web of Science ®Google Scholar
• SequistLVGettingerSSenzerNNActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerJ Clin Oncol201028334953496020940188
   PubMed Web of Science ®Google Scholar
• FelipECarcerenyEBarlesiFPhase II activity of the Hsp90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer [abstract]Ann Oncol201223Suppl 9438
   Google Scholar
• SocinskiMAGoldmanJEl-HariryIA multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerClin Cancer Res201319113068307723553849
   PubMed Web of Science ®Google Scholar
• SangJAcquavivaJFriedlandJCTargeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancerCancer Discov20133443044323533265
   PubMed Web of Science ®Google Scholar
• CostaDBShawATOuSHSolomonBJRileyGJAhnMJClinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasesJ Clin Oncol201533171881188825624436
   PubMed Web of Science ®Google Scholar
• GettingerSBazhenovaLSalgiaRALK Inhibitor AP26113 in patients with advanced malignancies, including ALKþ non–small cell lung cancer (NSCLC): updated efficacy and safety dataPoster presented at: Proceedings of the ESMO 2014 CongressSeptember 26–30, 2014Madrid, Spain. Lugano, SwitzerlandEuropean Society for Medical Oncology2014 Abstract no 1292P
   Google Scholar
• MaitlandMLOuS-HITolcherAWSafety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial designPoster presented at: Proceedings of the 50th Annual Meeting of American Society of Clinical OncologyMay 30–June 3, 2014Chicago, IL
   Google Scholar